奥施康定联合复方苦参注射液治疗肝癌晚期癌痛疗效观察

Observation on the curative effect of oxycontin combined with Compound Sophorae injection on cancer pain in patients with advanced liver cancer

目的探讨奥施康定联合复方苦参注射液治疗肝癌晚期癌痛的疗效,并对患者的生存质量进行评估。方法选取自2014年11月至2017年8月收治的56例伴有中重度癌痛的肝癌晚期姑息性治疗患者为研究对象。将所有患者随机分为A组(n=28)和B组(n=28)。A组患者给予奥施康定治疗,B组患者给予复方苦参联合奥施康定治疗。比较两组患者治疗后临床疗效、不良反应发生情况及体力状态改变情况。结果治疗第3天,A组总有效率(ORR)为46.4%(13/28),B组ORR为53.6%(15/28),两组比较,差异无统计学意义(P>0.05);治疗第7天,A组ORR为67.9%(19/28),显著低于B组的82.1%(23/28),两组比较,差异有统计学意义(P<0.05)。B组恶心呕吐、便秘及头晕乏力的发生率均显著低于A组,两组比较,差异均有统计学意义(P<0.05)。B组体力状态改善情况显著优于A组,两组比较,差异有统计学意义(P<0.05)。结论使用常规止疼药物治疗晚期肝癌患者癌痛时,联合应用复方苦参注射液可有效改善不良反应发生情况,提高终末期肝癌患者的生活质量。

Objective To investigate the effect of oxycontin combined with Compound Sophorae injection on cancer pain in patients with advanced liver cancer and to evaluate the quality of life of patients. Methods A retrospective study was performed on 56 cases of patients with advanced liver cancer who had moderate to severe cancer pain who were admitted from November 2014 to August2017. Patients were randomly divided into the Group A（ n = 28） and Group B（ n = 28）. Patients in Group A were treated with oxycontin,the others in Group B were treated with Compound Sophora combined with oxycontin. Results The overall response rate（ ORR）was 46. 4%（ 13/28） in Group A and 53. 6%（ 15/28） in Group B after three days of treatment,there was no statistically significant difference between the two groups（ P〈0. 05）; the ORR was 67. 9%（ 19/28） in Group A and 82. 1%（ 23/28） in Group B after 7 days of treatment（ P〉0. 05）. The incidence of nausea,vomiting,constipation and dizziness in Group B was significantly lower than that in Group A（ P〈0. 05）. The physical status of Group B improved significantly better than that in Group A（ P〈0. 05）.Conclusion When treating cancer pain of patients with advanced liver cancer with conventional painkillers,combined application of Compound Sophora injection can effectively improve adverse reactions and improve the quality of life of patients with advanced liver cancer.